Navigation Links
GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
Date:10/29/2008

PHILADELPHIA, Oct. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) (LSE: GSK) and Genelabs Technologies, Inc. (Nasdaq: GNLB) announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK's effort to develop and deliver novel therapies against the hepatitis C virus (HCV).

Under the terms of the agreement, a subsidiary of GSK will commence a tender offer to acquire all of the outstanding shares of Genelabs common stock. The board of directors of Genelabs has unanimously recommended that shareholders tender their shares in the offer.

"Genelabs has demonstrated a strong track record in HCV drug discovery and identified numerous novel classes of inhibitors that target unprecedented mechanisms in the virus's life cycle," stated Zhi Hong, SVP of the Infectious Diseases Centre for Excellence in Drug Discovery (ID CEDD) at GSK. "This arrangement, combined with our other collaborations, will give GSK a broad HCV drug discovery platform addressing novel targets and innovative therapeutic approaches."

Genelabs will become part of GSK's Drug Discovery organization and its HCV programs will be consolidated into the broad therapeutic approaches already underway internally and through external collaborations. This acquisition continues GSK's strategy of pursuing the best science, internally or externally, to bring new medicines to patients and value to the GSK pipeline.

Fred Driscoll, President & CEO of Genelabs said, "This transaction provides our shareholders with certain value at a substantial premium to our stoc
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
2. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
3. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
4. GlaxoSmithKline To Post Quarterly US Grants Report
5. GlaxoSmithKline - Q2 Results and Strategy Update - Interview with CEO
6. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
7. CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines from GlaxoSmithKline
8. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
9. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
10. GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience
11. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
(Date:10/27/2014)... 2014 The “Molecular Diagnostic Market ... Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, ... - Global Forecast to 2018” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
(Date:10/27/2014)... 2014 Called the NOAH Protocol, ... several types of pediatric brain cancer. The implications ... over 30 years of research and development. Amber ... that one mom's determination can make a difference. ... trick-or-treating, and it’s only fitting that we’ve received ...
(Date:10/27/2014)... , Oct. 27, 2014 Pressure ... a worldwide leader in the development and sale ... life sciences research market, today announced that Professor ... a novel, accurate, highly reproducible, and robust method ... routine high-throughput protein analysis on small needle biopsy ...
Breaking Biology Technology:Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5
... RAMAT GAN, Israel, June 8 EarlySense announced ... cleared for,marketing by the U.S. Food and Drug Administration ... Dutch notified body, in accordance with the,EC-Directive 93/42/EEC. Both ... home, hospital or clinical setting. In November 2007, EarlySense,announced ...
... Sirius Genomics, a developer of pharmacogenomic diagnostics, announced that ... its recent Annual General Meeting. The six-member Board consists ... Jim Heppell, Mr. Amos Michelson, Dr. Bradley Popovich and ... molecular diagnostics, commercialization and personalized medicine experience that is ...
... ... Pilest was recently selected by Solta Medical (parent company of Fraxel and Thermage) as ... more profound improvements when patients have undergone both procedures within a close time span. ... the cosmetic laser industry. , ...
Cached Biology Technology:EarlySense's EverOn(TM) System Receives FDA Clearance and CE Mark Certification 2Sirius Genomics Announces 2009 Board of Directors 2Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel & Thermage User Forum Held at Beckman Laser Institute 2Orange County Laser Surgeon Nissan Pilest Tapped as Keynote Speaker at Fraxel & Thermage User Forum Held at Beckman Laser Institute 3
(Date:10/29/2014)... registration is open for the Society ... Meeting. SIR 2015 is the one place ... and related health care professionals can come ... science and technologies being presented, discussed and ... in minimally invasive, image-guided medicine, SIR 2015 ...
(Date:10/29/2014)... on September 19, 2014, leading geneticist and humanitarian Prof. ... Sciences and Medicine at the University of Washington in ... Aviv University, was awarded the 2014 Lasker-Koshland Special Achievement ... honorary degree from TAU, Prof. King was the 2012-2013 ... for the past 18 years she has been the ...
(Date:10/29/2014)... Hebei, China — BGI Tech and Hebei Agricultural University ... Jujube genome. Jujube is the most economically important member ... particularly difficult to sequence due the high level of ... time that a genome in the Rhamnaceae (Buckthorn) family ... in Nature Communications . , Jujube ...
Breaking Biology News(10 mins):SIR 2015: Interventional radiology shapes tomorrow's medicine 2Geneticist and humanitarian: Prof. Mary-Claire King receives Lasker Award 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2
... examine the extent to which quercetin and trans-resveratrol ... cultures of human adipocytes treated with tumor necrosis ... and adipose tissue of obese, diabetic individuals. ... and trans-RSV followed by treatment with TNF-a. ...
... When prowling for a hook up, it,s not always the ... species of South American fish, brawn and stealth beat out ... series of published studies of a South American species of ... guppies, Syracuse University scientists have discovered how the interplay between ...
... environment, sea urchins literally eat through stone, using their teeth ... predators and protect themselves from the crashing surf on the ... rock-boring behavior is astonishing, scientists agree, but what is truly ... urchin teeth never, ever get dull. The secret of their ...
Cached Biology News:Study on effects of resveratrol and quercetin on inflammation and insulin resistance 2SU scientists find that in the evolutionary mating game, brawn and stealth rule 2SU scientists find that in the evolutionary mating game, brawn and stealth rule 3Ever-sharp urchin teeth may yield tools that never need honing 2
Component of GELase™ Agarose Gel-Digesting Preparation. 1 ml of 50X Buffer is sufficient for replacing the buffer in at least 5 g of gel....
...
... MagCellect Ferrofluid products perform optimally ... R&D Systems MagCellect Magnet. To ... neodymium iron boron permanent magnet ... 75 mm test tubes or ...
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
Biology Products: